New Zealand markets close in 3 hours 27 minutes
  • NZX 50

    11,170.08
    +80.05 (+0.72%)
     
  • NZD/USD

    0.5728
    -0.0001 (-0.01%)
     
  • NZD/EUR

    0.5737
    +0.0006 (+0.10%)
     
  • ALL ORDS

    7,014.00
    +108.70 (+1.57%)
     
  • ASX 200

    6,802.60
    +103.30 (+1.54%)
     
  • OIL

    86.54
    +0.02 (+0.02%)
     
  • GOLD

    1,732.70
    +2.20 (+0.13%)
     
  • NASDAQ

    11,582.54
    +352.81 (+3.14%)
     
  • FTSE

    7,086.46
    +177.70 (+2.57%)
     
  • Dow Jones

    30,316.32
    +825.43 (+2.80%)
     
  • DAX

    12,670.48
    +461.00 (+3.78%)
     
  • Hang Seng

    17,079.51
    -143.32 (-0.83%)
     
  • NIKKEI 225

    27,152.63
    +160.42 (+0.59%)
     
  • NZD/JPY

    82.3290
    -0.2340 (-0.28%)
     

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

·5-min read
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023

CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia

CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators

SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2022.

“Enrollment is on-track in our Phase 3 PATHFNDR program for paltusotine in acromegaly and our Phase 2 study in carcinoid syndrome, with results from these studies expected in 2023,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “We continue to validate the unique early de-risking efficiency of our endocrine drug development paradigm. CRN04894 is now our third program to successfully demonstrate pharmacologic proof-of-concept in Phase 1. We are now working with global regulators to align on clinical plans for both CRN04777 and CRN04894 with the goal of initiating clinical studies in congenital HI, Cushing’s disease, and CAH.”

Second Quarter 2022 and Recent Highlights

Second Quarter 2022 Financial Results

  • Research and development expenses were $33.0 million for the three months ended June 30, 2022, compared to $20.5 million for the same period in 2021. The increase was primarily attributable to an increase in spending on manufacturing and development activities of $7.6 million associated with clinical and nonclinical activities for paltusotine, CRN04777, CRN04894 and other preclinical programs, and an increase in personnel costs of $3.9 million.

  • General and administrative expenses were $10.5 million for the three months ended June 30, 2022, compared to $5.6 million for the same period in 2021. The increase was primarily attributable to an increase in personnel costs of $3.1 million.

  • Net loss for the three months ended June 30, 2022, was $42.4 million, compared to a net loss of $26.1 million for the same period in 2021.

  • Revenues were $0.4 million for the three months ended June 30, 2022, consisting of license revenue recognized from the license agreement entered into with Sanwa Kagaku Kenkyusho Co., Ltd. in February 2022.

  • Unrestricted cash, cash equivalents and investments totaled $408.5 million as of June 30, 2022, compared to $333.7 million as of December 31, 2021.

  • The company had 53,752,778 common shares outstanding as of August 9, 2022.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, a somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and for CRN04894, an investigational, oral ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of paltusotine, CRN04777 and CRN04894, including the therapeutic potential and clinical benefits thereof; the expected timing of data from the ongoing Phase 3 clinical trials of paltusotine in acromegaly and Phase 2 clinical trial of paltusotine in carcinoid syndrome; Crinetics’ plans to advance CRN04777 and CRN04894 into Phase 2 clinical trials and the timing thereof; plans to meet with regulators and to advance CRN04894 into a clinical program in patients for the treatment of Cushing’s disease and congenital adrenal hyperplasia and to advance CRN04777 into a clinical program in patients for the treatment of congenital hyperinsulinism and the timing thereof; Crinetics’ anticipated cash runway and plans to advance other pipeline product candidates or discovery efforts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, top-line data that we report may change following a more comprehensive review of the data related to the clinical trials and such data may not accurately reflect the complete results of a clinical trial, and the FDA and other regulatory authorities may not agree with our interpretation of such results; advancement of CRN04894 and CRN04777 into later stage trials is dependent on and subject to the receipt of further feedback from the FDA and other regulatory agencies; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the company’s product candidates that may limit their development, regulatory approval and/or commercialization; the company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics’ clinical trials and nonclinical studies; regulatory developments in the United States and foreign countries; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; Crinetics may use its capital resources sooner than expected; any future impacts to our business resulting from the conflict between Russia and Ukraine or other geopolitical developments outside our control; and the other risks and uncertainties described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic reports, including its annual report on Form 10-K for the year ended December 31, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

STATEMENTS OF OPERATIONS DATA:

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

License revenues

 

$

439

 

 

$

 

 

$

3,570

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

32,995

 

 

 

20,487

 

 

 

61,247

 

 

 

38,071

 

General and administrative

 

 

10,489

 

 

 

5,602

 

 

 

19,195

 

 

 

10,936

 

Total operating expenses

 

 

43,484

 

 

 

26,089

 

 

 

80,442

 

 

 

49,007

 

Loss from operations

 

 

(43,045

)

 

 

(26,089

)

 

 

(76,872

)

 

 

(49,007

)

Total other income (expense), net

 

 

670

 

 

 

(6

)

 

 

880

 

 

 

11

 

Loss before equity method investment

 

__

 

 

__

 

 

 

(75,992

)

 

 

(48,996

)

Loss on equity method investment

 

 

 

 

 

 

 

 

(1,010

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(42,375

)

 

$

(26,095

)

 

$

(77,002

)

 

$

(48,996

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.81

)

 

$

(0.70

)

 

$

(1.54

)

 

$

(1.40

)

Weighted-average shares - basic and diluted

 

 

52,522

 

 

 

37,061

 

 

 

50,130

 

 

 

35,048

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


BALANCE SHEET DATA:

 

June 30,
2022

 

 

December 31,
2021

 

 

 

 

 

 

 

 

Cash, cash equivalents and investments

 

$

408,506

 

 

$

333,707

 

Working capital

 

$

390,170

 

 

$

328,725

 

Total assets

 

$

421,733

 

 

$

351,015

 

Total liabilities

 

$

35,568

 

 

$

19,071

 

Accumulated deficit

 

$

(352,257

)

 

$

(275,255

)

Total stockholders’ equity

 

$

386,165

 

 

$

331,944

 

Contact: 
Chas Schultz 
VP, IR & Corporate Communications 
cschultz@crinetics.com 
(858) 450-6464

Investors / Media: 
Corey Davis 
LifeSci Advisors, LLC 
cdavis@lifesciadvisors.com 
(212) 915-2577

Aline Sherwood 
Scienta Communications 
asherwood@scientapr.com 
(312) 238-8957